Tangible Shareholders Equity: The value shareholders equity less intangible assets.
CytoMed Therapeutics Limited (GDTC) had Tangible Shareholders Equity of $6.55M for the most recently reported fiscal quarter, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$4.39M |
|
$3.67M |
|
$4.27M |
|
$7.37M |
|
$0.44M |
|
$0.31M |
|
$0.31M |
|
$0.75M |
|
$6.62M |
|
|
Tangible Shareholders Equity |
$6.55M |
$6.62M |
|
-- |
|
| Cash Flow Statement Financials | |
$-1.98M |
|
$0.82M |
|
$-0.05M |
|
$4.56M |
|
$3.44M |
|
$-1.12M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|